Initial Results of a Multicenter Phase II Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer

Here we report the initial outcomes of an international multi-center phase II prospective trial assessing the role of stereotactic ablative radiotherapy (SABR) for oligometastatic cancer. Our results demonstrate SABR to be a safe an effective treatment modality that demonstrates excellent overall survival and local control. Additionally, we report very low rates of acute and late grade 3 toxicity and show SABR to have no significant adverse effect on patient reported quality of life.

https://ift.tt/2Lobnxe